<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04223804</url>
  </required_header>
  <id_info>
    <org_study_id>M19-939</org_study_id>
    <secondary_id>2019-004866-16</secondary_id>
    <nct_id>NCT04223804</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With HIV-1</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of ABBV-181 in HIV-1 Infected Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted in two stages and will test the safety/tolerability,
      pharmacokinetics (how the body handles study drug) and pharmacodynamics (effects on the
      immune system and the virus) of the study drug ABBV-181 in HIV-1 infected participants
      undergoing ART interruption.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 30, 2020</start_date>
  <completion_date type="Anticipated">March 14, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 20, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Study Drug-Related Adverse Events Grade 3 or Higher</measure>
    <time_frame>Up to approximately 44 weeks</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of the study drug as either having a reasonable possibility or no reasonable possibility. AEs are given a grade from 1-5 with Grade 3 being severe but not life-threatening and requiring hospitalization, Grade 4 being life-threatening requiring immediate intervention and Grade 5 being death related to an AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Study Drug-Related Immune-Related Adverse Events (IRAE)</measure>
    <time_frame>Up to approximately 44 weeks</time_frame>
    <description>Assessed using the American Society of Clinical Oncology (ASCO) IRAE management guidelines (which utilizes the NIH CTCAE grading scale) but modified, as applicable, according to the NIH Division of AIDS (DAIDS) (v2.1) AE grading scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events (AEs) Corresponding to Retroviral Rebound Syndrome</measure>
    <time_frame>Up to approximately 44 weeks</time_frame>
    <description>Adverse Events (AEs) Corresponding to Retroviral Rebound Syndrome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Concentration (Cmax)</measure>
    <time_frame>Up to approximately 28 weeks</time_frame>
    <description>Maximum Observed Concentration (Cmax) of ABBV-181</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax)</measure>
    <time_frame>Up to approximately 28 weeks</time_frame>
    <description>Time to Cmax (Tmax) of ABBV-181</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Concentration (Ctrough)</measure>
    <time_frame>Up to approximately 28 weeks</time_frame>
    <description>Observed Concentration (Ctrough) at the end of the 4-week dosing interval for ABBV-181.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve (AUCtau)</measure>
    <time_frame>Up to approximately 28 weeks</time_frame>
    <description>Area Under the Curve (AUCtau) during the 4-week dosing interval for ABBV-181.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life (t1/2)</measure>
    <time_frame>Up to approximately 28 weeks</time_frame>
    <description>Half-life (t1/2) of ABBV-181 for the second dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peripheral PD-1 Receptor Saturation</measure>
    <time_frame>Up to approximately 28 weeks</time_frame>
    <description>Peripheral PD-1 Receptor Saturation on CD4+ and CD8+ T cell subsets.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Human Immunodeficiency Virus (HIV)</condition>
  <condition>HIV Infection</condition>
  <condition>HIV-1</condition>
  <arm_group>
    <arm_group_label>Stage 2: Arm F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ABBV-181 dose D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: Arm E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ABBV-181 dose C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: Arm D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ABBV-181 dose B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ABBV-181 dose A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: Arm A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-181</intervention_name>
    <description>Intravenous (IV) infusion</description>
    <arm_group_label>Stage 1: Arm B</arm_group_label>
    <arm_group_label>Stage 1: Arm C</arm_group_label>
    <arm_group_label>Stage 2: Arm E</arm_group_label>
    <arm_group_label>Stage 2: Arm F</arm_group_label>
    <other_name>Budigalimab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous (IV) infusion</description>
    <arm_group_label>Stage 1: Arm A</arm_group_label>
    <arm_group_label>Stage 2: Arm D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index (BMI) &gt;= 18.0 to &lt;35 kg/m2

          -  HIV-1 infected on antiretroviral therapy (ART) for at least 12 months prior to
             screening and on current ART regimen for at least 12 weeks prior to screening.

          -  Meets HIV-specific laboratory parameters as below:

               -  Plasma HIV-1 RNA below lower limit of detection (LLOD) at screening and at least
                  6 months prior to screening

               -  CD4+ T cell count &gt;= 500 cells/uL at screening and at least once during the 12
                  months prior to screening

               -  CD4+ T cell nadir of &gt;= 350 cells/uL during chronic infection

          -  Willing to undergo ART interruption

          -  Agrees to use an effective barrier method of protection (male and/or female condoms)
             during sexual activity for protection against HIV-1 transmission throughout the entire
             study

        Exclusion Criteria:

          -  Known resistance to &gt;= 2 classes of ART

          -  History of AIDS-defining illness

          -  Active or suspected malignancy or history of malignancy (other than basal cell skin
             cancer or cervical carcinoma in situ) in the past 5 years

          -  History of or active immunodeficiency (other than HIV)

          -  Active autoimmune disease or history of autoimmune disease that has required systemic
             treatment

          -  Prior receipt of immunomodulatory or immunosuppressive (including intravenous infusion
             or oral steroids at any dose, but excluding steroids that are inhaled, topical or by
             local injection) therapy within 6 months prior to the first dose of study drug

          -  Current hepatitis B virus or hepatitis C virus infection

          -  Female participants must not be pregnant, breastfeeding, or considering becoming
             pregnant during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham - Main /ID# 216568</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Felizarta /ID# 215721</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Quest Clinical Research /ID# 215796</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115-3037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>George Washington University Medical Faculty Associates /ID# 213893</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037-3201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Midway Immunology and Research /ID# 215587</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Miami, Miller School of Medicine /ID# 213833</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine /ID# 215589</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-2927</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester /ID# 217820</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905-0001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati /ID# 215615</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0585</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prism Health North Texas /ID# 214036</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75208-4599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital, Darlinghurst /ID# 215354</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Holdsworth House Medical Practice /ID# 215352</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital /ID# 217077</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital /ID# 215351</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital /ID# 218083</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>McGill Univ Clinical Research /ID# 218081</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Antoine /ID# 218060</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Puerto Rico AIDS Clinical Trials Unit CRS /ID# 213761</name>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 8, 2020</study_first_submitted>
  <study_first_submitted_qc>January 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2020</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human Immunodeficiency Virus (HIV)</keyword>
  <keyword>HIV Infection</keyword>
  <keyword>HIV-1</keyword>
  <keyword>ABBV-181</keyword>
  <keyword>Analytical Treatment Interruption</keyword>
  <keyword>Budigalimab</keyword>
  <keyword>Programmed cell death protein-1 (PD-1)</keyword>
  <keyword>Anti-PD-1 Antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

